TherapeuticsMD Q3 EPS $(0.13) Misses $(0.05) Estimate
Portfolio Pulse from Benzinga Newsdesk
TherapeuticsMD (NASDAQ:TXMD) reported a Q3 EPS loss of $(0.13), missing the consensus estimate of $(0.05) by 160%. Despite the miss, this represents a significant improvement from the $(2.75) per share loss in the same quarter last year.
November 14, 2023 | 9:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TherapeuticsMD reported a larger-than-expected Q3 loss per share of $(0.13), which did not meet the $(0.05) analyst estimate. However, the loss has narrowed significantly from the previous year's $(2.75) per share.
The earnings miss is likely to negatively impact investor sentiment in the short term, as the company did not meet analyst expectations. However, the significant year-over-year improvement in losses may provide some positive sentiment offset.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100